ClinicalTrials.gg
CompletedNCT06068946VENTUREUpdated Feb 12, 2025

VK2735 for Weight Management Phase 2

A Phase 2 interventional study of VK2735 and Placebo in Weight Loss, sponsored by Viking Therapeutics, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-12.

Primary conditionOverweightRegistry: Weight LossReclassifiedWhy we changed it
Registry
Weight Loss — the first condition term the registry derived for this study.
ClinicalTrials.gg
Overweight
Why
  1. Weight Loss is a broad heading, used only when no more specific condition is named.
  2. The study's title name Overweight.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Viking Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,479 studies in Overweight with a site in United States — 273 open to participants now, 400 under way, 69 of them phase 3. Overweight · United States.

Enrollment
443rd of 1,365
176 · median 85
Started
2023
with 92 others
Phase 2
147 of 1,479
29 open now
Registered
1,027th of 1,479
by date

Among the 1,479 studies in Overweight with a site in United States, this one is the 443rd largest by enrollment of the 1,365 interventional ones that give a count, is one of 93 that started in 2023, is one of 147 in phase 2, and was the 1,027th registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

Browse Overweight studies →

Open to participants now

273 of the 1,479 studies in Overweight with a site in United States are open now. Recruiting first, the newest first:

268 more — sign in →

All 273 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 534 Overweight studies recruiting now, 159 (30%) set no upper age limit and 347 (65%) stop at 75 or younger; 64 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,479 studies in Overweight with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.

VK2735 or matched placebo will be administered once weekly.

03

Conditions studied

  • Weight Loss

Browse trials for

Keywords

  • Overweight
  • Obese
04

In context

Overweight Reclassified

3,613 studies on the registry are indexed under Overweight; 861 are open to participants now.

This study's enrollment of 176 is above the median of 78 across 3,132 interventional studies indexed under Overweight.

Browse Overweight studies →

Lead sponsor

Viking Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; 4 are open to participants now.

Compared within Overweight, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Weight Loss. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years of age at the time of signing the
  2. (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI \<50 kg/m2

Exclusion criteria

Exclusion Criteria:

  1. History of or current medical or psychiatric disorder that, in the opinion of the Investigator, does not support study participation
  2. Self-reported body weight change of 5% or more within 3 months of screening
  3. Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)
  4. Current or past diagnosis of chronic pancreatitis
  5. Calcitonin ≥20 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)
  6. Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening
  7. Any prescription or over-the-counter medications intended for weight loss within 6 months of screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
176 participants (actual)

Study arms

  • Placebo comparator
    VK2735 (Placebo)

    Placebo

    Biological: Placebo

  • Experimental
    VK2735 (Dose #1)

    VK2735 is a peptide GLP-1 and GIP dual agonist

    Biological: VK2735

  • Experimental
    VK2735 (Dose #2)

    VK2735 is a peptide GLP-1 and GIP dual agonist

    Biological: VK2735

  • Experimental
    VK2735 (Dose #3)

    VK2735 is a peptide GLP-1 and GIP dual agonist

    Biological: VK2735

  • Experimental
    VK2735 (Dose #4)

    VK2735 is a peptide GLP-1 and GIP dual agonist

    Biological: VK2735

Interventions

  • BiologicalVK2735

    VK2735 is a peptide GLP-1 and GIP dual agonist

  • BiologicalPlacebo

    Placebo comparator

07

What researchers measure

Primary outcomes

  1. Percent (relative) change from baseline to Week 13 in body weight

    To measure the efficacy of VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition

    Time frame: 13 weeks

Secondary outcomes

  1. Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13

    To measure the efficacy of VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition

    Time frame: 13 weeks

Other outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs), TESAEs, AESI

    To evaluate the safety and tolerability of VK2735 for weight loss in adult Subjects who are obese, or overweight with at least one weight-related comorbid condition

    Time frame: 13 weeks

08

Study locations

20 sites
  • Viking Clinical Site #119
    Birmingham, Alabama 35235, United States
  • Viking Clinical Site #114
    Long Beach, California 90815, United States
  • Viking Clinical Site #110
    Los Angeles, California 90057, United States
  • Viking Clinical Site #113
    Tustin, California 92780, United States
  • Viking Clinical Site #116
    Clearwater, Florida 33756, United States
  • Viking Clinical Site #106
    Clearwater, Florida 33761, United States
  • Viking Clinical Site #112
    Jacksonville, Florida 32216, United States
  • Viking Clinical Site #105
    Ocoee, Florida 34761, United States
  • Viking Clinical Site #107
    Port Orange, Florida 32127, United States
  • Viking Clinical Site #104
    Indianapolis, Indiana 46260, United States
  • Viking Clinical Site #103
    Louisville, Kentucky 40213, United States
  • Viking Clinical Site #109
    Marrero, Louisiana 70072, United States
  • Viking Clinical Site #102
    Kansas City, Missouri 64131, United States
  • Viking Clinical Site #111
    Butte, Montana 59701, United States
  • Viking Clinical Site #108
    Knoxville, Tennessee 37920, United States
  • Viking Clinical Site #101
    Austin, Texas 78705, United States
  • Viking Clinical Site #118
    Austin, Texas 78731, United States
  • Viking Clinical Site #100
    Phoenix, Texas 85210, United States
  • Viking Clinical Site #115
    San Antonio, Texas 78229, United States
  • Viking Clinical Site #117
    San Antonio, Texas 78229, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Feb 2024, 5 months.

Of 102 industry-sponsored phase 2 interventional studies under Overweight, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 148 studies reached it within 13 months; a quarter within 8 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2023
First posted
Oct 5, 2023
StartActual
Aug 31, 2023
Primary completionActual
Feb 27, 2024
CompletionActual
Apr 2, 2024
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06068946
Responsible party
Sponsor
First posted
Oct 5, 2023
Start date
Aug 31, 2023
Primary completion
Feb 27, 2024
Completion
Apr 2, 2024
Last update
Feb 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VK2735

Start the discussion